BBIO

BridgeBio Pharma Inc
$77.24-$0.94-1.21%Price as of Nov 20, 2026, 10:30 AM ET

Key stats

Market cap
15.0B
Open
—
Day range
—
52-week range
$62.50 – $93.42
Volume
122K
Avg volume
2.96M

Earnings

Q3 FY26Beat
Expected$-0.59
Actual$-0.42
Q2 FY26
Actual$-0.78
Q1 FY26
Actual$-0.84
Q4 FY25
Actual$-1.00

Next earnings call Feb 22, 2027

About

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees
839
Headquarters
Palo Alto, CA